Увійти

Готові списки джерел за темами / 346.12:658.821 (477)

Зміст

Статті в журналах

Добірка наукової літератури з теми "346.12:658.821 (477)"

Автор: Grafiati

Опубліковано: 30 травня 2022

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "346.12:658.821 (477)".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "346.12:658.821 (477)"

1

Leontev, A. V., A. I. Khalimon, M/ M/ Khodzhibekova, et al. "Value of [18F]FDG PET/CT for predicting epidermal growth factor receptor gene mutation status in patients with newly diagnosed non-small cell lung cancer: a retrospective single center study." Research and Practical Medicine Journal 12, no. 2 (2025): 46–59. https://doi.org/10.17709/2410-1893-2025-12-2-4.

Повний текст джерела

Анотація:

Purpose of the study. The aim of this study was to evaluate the role of [18F]FDG PET/CT for predicting epidermal growth factor receptor (EGFR) gene mutation status in patients with newly diagnosed non-small cell lung cancer (NSCLC).Patients and methods. This retrospective single center study included 63 patients with NSCLC who underwent [18F]FDG PET/ CT and were divided into the mutant (n = 30) and wild-type groups (n = 33) based on EGFR mutation status. Maximal diameter (Dmax) and anatomical volume of each primary tumor lesion were measured, [18F]FDG uptake was analyzed by measurement of SUVm

Стилі APA, Harvard, Vancouver, ISO та ін.

2

De Agustin, J. J., G. Añez, D. Reina-Sanz, et al. "AB1116 APREMILAST IN PSORIATIC ARTHRITIS. ULTRASOUND ANALYSIS (JOINT-ENTHESES-UNGUEAL INDEX) OF THE EFFICACY AND VARIABLES CORRELATION STUDY." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1787–88. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1397.

Повний текст джерела

Анотація:

BackgroundWe conducted a study using ultrasonography (US) to evidence inflammatory changes (joint-enthesis-ungueal) in active PsA (aPsA) patients who started Apremilast (A) in clinical practice.ObjectivesObtain a 20, 50, 70 % reduction in the US index (UIC) at 12 months, and study correlation between variables.MethodsPhase IV, multicenter, prospective and open-label clinical trialconductedin 9 centresfrom 2018 to 2021. All patients signed the informed consent. Approval by the ethical committee was obtained, code PSA-PI-006421. PsA patients (≥ 2 swollen joints), ≥ 2 joint US synovitis and ≥ 1 U

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Lazo-Langner, Alejandro, Jeff Hawell, Michael J. Kovacs, et al. "A Systematic Review and Meta-Analysis of Proportions of Thrombosis and Bleeding in Patients Receiving Venous Thromboembolism (VTE) Prophylaxis After Orthopedic Surgery (OS). An Update." Blood 114, no. 22 (2009): 3125. http://dx.doi.org/10.1182/blood.v114.22.3125.3125.

Повний текст джерела

Анотація:

Abstract Abstract 3125 Poster Board III-62 VTE is the most frequent complication of OS and it can be prevented through anticoagulant prophylaxis. Numerous studies have evaluated different agents for this purpose and there are new agents currently under development or recently approved for this indication. We conducted a systematic review of randomized controlled trials (RCT) evaluating administration of anticoagulants for VTE prophylaxis in OS and performed a MA of proportions to estimate the overall incidence of major VTE (proximal VTE, pulmonary embolism (PE), or death from PE), total VTE (p

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Gomes, Marília de Brito, Gildásio R. da Silva Júnior, and Eliete Leão da S. Clemente. "Variabilidade da pressão arterial de consultório em pacientes com diabetes mellitus do tipo 1." Arquivos Brasileiros de Endocrinologia & Metabologia 43, no. 2 (1999): 96–103. http://dx.doi.org/10.1590/s0004-27301999000200005.

Повний текст джерела

Анотація:

Objetivo: Analisar a associação da variabilidade da pressão arterial auscultatória sistólica (PAS) e diastólica (PAD) com variáveis clínicas do diabetes tipo 1 (DM1). Métodos: Foram estudados 58 pacientes com DM1 (33 mulheres) com 24,6±8,5 (9-43) anos e duração do diabetes de 8,4±6,6 (0,4-36) anos, sendo 46 adultos e 12 púberes. A PAS e a PAD foram aferidas em três diferentes dias na posição supina, antes e após 5 e 10 min de repouso, calculando-se o coeficiente de variação médio (CVM) e intra-individual (CVI). Resultados; O CVM da PAS entre os diferentes tempos de aferição variou de 3,0 a 3,6

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Van der Heijde, D., L. S. Gensler, A. Deodhar, et al. "OP0105 EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 68–69. http://dx.doi.org/10.1136/annrheumdis-2020-eular.323.

Повний текст джерела

Анотація:

Background:Bimekizumab (BKZ), a monoclonal antibody that selectively neutralises interleukin (IL)-17A and IL-17F, is a potential therapeutic option in ankylosing spondylitis (AS).Objectives:To report 48-week (wk) patient-reported outcomes (PROs) in patients (pts) with AS treated with BKZ in a phase 2b dose-ranging study (BE-AGILE;NCT02963506).Methods:Pts with active AS (Bath AS Disease Activity Index [BASDAI] ≥4; spinal pain ≥4 [0–10]), fulfilling modified New York criteria (central reading), and inadequate response/intolerance to NSAIDs were randomised according to the study design (Figure 1)

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Strand, V., E. Choy, E. Nasonov, et al. "POS0291 OLOKIZUMAB IMPROVED PATIENT REPORTED OUTCOMES IN TNF INCOMPLETE RESPONDER (TNF-IR) RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM THE PHASE 3 RANDOMIZED CONTROLLED TRIAL, CREDO 3." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 390.2–391. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1990.

Повний текст джерела

Анотація:

BackgroundOlokizumab (OKZ) is an interleukin-6-inhibitor for treatment of rheumatoid arthritis (RA). In these analyses we present patient reported outcomes (PROs) reported by TNF-IR patients with moderate to severely active RA receiving OKZ or placebo in a phase 3 randomized controlled trial (RCT) (ClinicalTrials.gov number, NCT02760433).ObjectivesTo assess the effect of OKZ treatment compared with placebo in patient global assessment of disease activity (PtGA), pain, physical function (HAQ-DI), fatigue (FACIT-F) and health related quality of life (SF-36 physical (PCS) and mental (MCS) compone

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Zdenek, Racil, Petra Belohlavkova, Petr Cetkovsky, et al. "Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study." Blood 124, no. 21 (2014): 1813. http://dx.doi.org/10.1182/blood.v124.21.1813.1813.

Повний текст джерела

Анотація:

Abstract Background: Recently we have published results of pilot study on CML patients demonstrating fast development of hyperinsulinaemia, peripheral insulin resistance, hypoadiponectinaemia and hypercholesterolemia during nilotinib therapy. Aims: To analyze results from follow up multicenter study “ENIGMA 2” with the aim to confirm or to exclude results from the pilot study, as well as to analyze whether these abnormalities are detected in control groups of patients treated with other TKIs - imatinib and dasatinib. Methods: Patients received intensive laboratory workup before the start of TK

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Weissmann, Sandra, Andreas Roller, Vera Grossmann, et al. "Prognostic Impact of NOTCH1 Mutations in Chronic Lymphocytic Leukemia (CLL): A Study On 538 Patients." Blood 120, no. 21 (2012): 2873. http://dx.doi.org/10.1182/blood.v120.21.2873.2873.

Повний текст джерела

Анотація:

Abstract Abstract 2873 Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Recurrent activating mutations of NOTCH1 have been reported, including the relevance of NOTCH1 mutations as independent negative prognostic marker (Rossi et al., Blood 2012). Aims: 1. Determine the frequency and prognostic impact of NOTCH1 mutations (NOTCH1 mut) in a large unselected cohort of adult CLL patients. 2. Evaluate the range of mutational burden by amplicon deep-sequencing. Patients and Methods: We investigated 538 patients (189 female, 349 male; median age: 66.1 years, range:

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Fahey, Margaret C., Marion E. Hare, Gerald W. Talcott, et al. "Characteristics Associated With Participation in a Behavioral Weight Loss Randomized Control Trial in the U.S. Military." Military Medicine 184, no. 3-4 (2018): e120-e126. http://dx.doi.org/10.1093/milmed/usy199.

Повний текст джерела

Анотація:

Abstract Introduction Effective recruitment and subsequent enrollment of diverse populations is often a challenge in randomized controlled trials, especially those focused on weight loss. In the civilian literature, individuals identified as racial and ethnic minorities, men, and younger and older adults are poorly represented in weight loss interventions. There are limited weight loss trials within military populations, and to our knowledge, none reported participant characteristics associated with enrollment. There may be unique motives and barriers for active duty personnel for enrollment i

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Symons, Heather J., Chimene Kesserwan, Ferdynand Kos, et al. "Favorable Immune Reconstitution After Nonmyeloablative, T-Cell Replete, HLA-Haploidentical BMT with Post-Transplant Cyclophosphamide." Blood 118, no. 21 (2011): 1009. http://dx.doi.org/10.1182/blood.v118.21.1009.1009.

Повний текст джерела

Анотація:

Abstract Abstract 1009 Delayed immune reconstitution with increased risk of opportunistic infection is a major complication of HLA-haploidentical stem cell transplantation, especially in protocols employing extensive T cell depletion of the graft. Previous studies at our institution with high-dose, post-transplantation Cy (PT/Cy) have reported low rates of non-relapse mortality and serious opportunistic infections. Here we characterize immune reconstitution in fifty-three consecutive hematologic malignancies patients receiving nonmyeloablative conditioning, T cell-replete, HLA-haploidentical b

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!